                </a></li></ul></div><p><strong>Figure 2.  <span>HIV-1 subtype B and C viruses with primary resistance mutations from individuals undergoing HAART.</span></strong></p><a id="article1.body1.sec3.sec1.fig2.caption1.p1" name="article1.body1.sec3.sec1.fig2.caption1.p1"></a><p>Different treatment exposure periods (in months) were plotted for each subtype and for each ARV drug class. (A) NRTI, (B) NNRTI, (C) PI. Black asterisks denote significance in the difference of proportions between subtypes B and C at the 0.05 <em>p</em> value level.</p>
